PP 1131

Drug Profile

PP 1131

Alternative Names: P. aeruginosa phages cocktail - Pherecydes; PHAGOBURN Pseudomonas phage therapy - Pherecydes; PP1131

Latest Information Update: 19 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pherecydes Pharma
  • Class Pseudomonas phages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Burn infections; Pseudomonal infections

Most Recent Events

  • 01 Jul 2015 Phase-I/II clinical trials in Burn infections in France (Topical) (NCT02116010)
  • 01 Jul 2015 Phase-I/II clinical trials in Pseudomonal infections in France (Topical) (NCT02116010)
  • 04 Jun 2014 Pherecydes Pharma plans a phase I/II trial for Burn infections caused by Pseudomonas aeruginosa in Belgium, France and Switzerland (Topical) (NCT02116010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top